文献速递生殖医学产科

复发性妊娠丢失评估联合流产组织24染色体微阵列分析可为超过90%的患者提供可能或明确的妊娠丢失原因

Recurrent pregnancy loss evaluation combined with 24-chromosome microarray of miscarriage tissue provides a probable or definite cause of pregnancy loss in over 90% of patients.
PubMed 文献 · Hum Reprod · 2018-01-01

该单中心前瞻性队列研究纳入2014至2017年100例复发性妊娠丢失(RPL)患者,均完成美国生殖医学学会(ASRM)标准评估及流产组织24染色体微阵列分析。结果显示,联合评估可在95/100(95%)患者中明确可能或肯定原因,而仅ASRM评估为45/100(45%);初始微阵列分析可节省50%成本。

要点

  • 联合流产组织24染色体微阵列与ASRM评估可在95%的RPL患者中明确可能或肯定原因。
  • 仅ASRM评估仅能解释45%的妊娠丢失,初始微阵列分析可识别67%的明确异常。
  • 初始采用流产组织微阵列分析可为医疗系统和患者节省50%成本。

核心结论

  • 联合流产组织24染色体微阵列分析与ASRM标准评估可在超过90%的RPL患者中明确可能或肯定原因。

研究设计与样本

  • 单中心前瞻性队列研究,纳入2014至2017年一家私立RPL诊所的100例患者,均有两次或以上妊娠丢失并完成ASRM定义的完整评估及第二次或后续流产后的流产组织24染色体微阵列分析。

主要发现

  • 联合评估在95/100(95%)的RPL患者中明确可能或肯定原因。
  • 仅ASRM RPL评估在45/100(45%)患者中识别异常及可能解释。
  • 初始流产组织24染色体微阵列分析在67/100(67%)患者中识别明确异常。
  • 仅5/100(5%)患者为整倍体丢失且ASRM评估正常,未找到可能或肯定原因。
  • 成本分析表明初始采用流产组织24染色体微阵列分析可使医疗系统和患者节省50%成本。

临床怎么用

  • 作者建议所有连续两次或以上妊娠丢失的夫妇在第二次及后续流产时接受流产组织遗传学评估。
  • 作者认为流产组织遗传学评估联合基于证据的RPL评估可在超过90%的流产中明确可能或肯定原因。

局限性

  • 本研究为单中心研究,样本为特征明确的小样本RPL女性。
  • 评估后的后续妊娠结局随访不完整,但作者认为不应影响主要结果。
  • 患者年龄范围为26至45岁,年龄较大者尤其是35岁以上预期会有更多非整倍体妊娠丢失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Will the addition of 24-chromosome microarray analysis on miscarriage tissue combined with the standard American Society for Reproductive Medicine (ASRM) evaluation for recurrent miscarriage explain most losses? SUMMARY ANSWER: Over 90% of patients with recurrent pregnancy loss (RPL) will have a probable or definitive cause identified when combining genetic testing on miscarriage tissue with the standard ASRM evaluation for recurrent miscarriage. WHAT IS KNOWN ALREADY: RPL is estimated to occur in 2-4% of reproductive age couples. A probable cause can be identified in approximately 50% of patients after an ASRM recommended workup including an evaluation for parental chromosomal abnormalities, congenital and acquired uterine anomalies, endocrine imbalances and autoimmune factors including antiphospholipid syndrome. STUDY DESIGN, SIZE, DURATION: Single-center, prospective cohort study that included 100 patients seen in a private RPL clinic from 2014 to 2017. All 100 women had two or more pregnancy losses, a complete evaluation for RPL as defined by the ASRM, and miscarriage tissue evaluated by 24-chromosome microarray analysis after their second or subsequent miscarriage. PARTICIPANTS/MATERIALS, SETTING, METHODS: Frequencies of abnormal results for evidence-based diagnostic tests considered definite or probable causes of RPL (karyotyping for parental chromosomal abnormalities, and 24-chromosome microarray evaluation for products of conception (POC); pelvic sonohysterography, hysterosalpingogram, or hysteroscopy for uterine anomalies; immunological tests for lupus anticoagulant and anticardiolipin antibodies; and blood tests for thyroid stimulating hormone (TSH), prolactin and hemoglobin A1c) were evaluated. We excluded cases where there was maternal cell contamination of the miscarriage tissue or if the ASRM evaluation was incomplete. A cost analysis for the evaluation of RPL was conducted to determine whether a proposed procedure of 24-chromome microarray evaluation followed by an ASRM RPL workup (for those RPL patients who had a normal 24-chromosome microarray evaluation) was more cost-efficient than conducting ASRM RPL workups on RPL patients followed by 24-chromosome microarray analysis (for those RPL patients who had a normal RPL workup). MAIN RESULTS AND THE ROLE OF CHANCE: A definite or probable cause of pregnancy loss was identified in the vast majority (95/100; 95%) of RPL patients when a 24-chromosome pair microarray evaluation of POC testing is combined with the standard ASRM RPL workup evaluation at the time of the second or subsequent loss. The ASRM RPL workup identified an abnormality and a probable explanation for pregnancy loss in only 45/100 or 45% of all patients. A definite abnormality was identified in 67/100 patients or 67% when initial testing was performed using 24-chromosome microarray analyses on the miscarriage tissue. Only 5/100 (5%) patients, who had a euploid loss and a normal ASRM RPL workup, had a pregnancy loss without a probable or definitive cause identified. All other losses were explained by an abnormal 24-chromosome microarray analysis of the miscarriage tissue, an abnormal finding of the RPL workup, or a combination of both. Results from the cost analysis indicated that an initial approach of using a 24-chromosome microarray analysis on miscarriage tissue resulted in a 50% savings in cost to the health care system and to the patient. LIMITATIONS, REASONS FOR CAUTION: This is a single-center study on a small group of well-characterized women with RPL. There was an incomplete follow-up on subsequent pregnancy outcomes after evaluation, however this should not affect our principal results. The maternal age of patients varied from 26 to 45 years old. More aneuploid pregnancy losses would be expected in older women, particularly over the age of 35 years old. WIDER IMPLICATIONS OF THE FINDINGS: Evaluation of POC using 24-chromosome microarray analysis adds significantly to the ASRM recommended evaluation of RPL. Genetic evaluation on miscarriage tissue obtained at the time of the second and subsequent pregnancy losses should be offered to all couples with two or more consecutive pregnancy losses. The combination of a genetic evaluation on miscarriage tissue with an evidence-based evaluation for RPL will identify a probable or definitive cause in over 90% of miscarriages. STUDY FUNDING/COMPETING INTEREST(S): No funding was received for this study and there are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Popescu F, Jaslow CR, Kutteh WH, et al. Recurrent pregnancy loss evaluation combined with 24-chromosome microarray of miscarriage tissue provides a probable or definite cause of pregnancy loss in over 90% of patients. Hum Reprod. 2018. PMID: 29538673. doi:10.1093/humrep/dey021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。